Trends Towards Standardisation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Trends Towards Standardisation


Pharmaceutical Technology Europe
Volume 23, Issue 2

Standardising Quality Agreements

One area that can benefit from a form of standardisation is Quality Agreements. In a recent editorial I wrote for PTE (October 2010; available at http://www.pharmtech.com/jmartin), I discussed a new initiative by the BPSA to develop a Quality Agreement Template for singleuse suppliers and users. The FDA has provided guidance on establishing quality agreements with contract manufacturers of licensed biologics, and drug manufacturers are seeking similar agreements with all their suppliers, including equipment.1 The Society of Chemical Manufacturers and Affiliates (SOCMA), home to the BPSA, has a Bulk Pharmaceuticals Task Force that has developed a Template for Quality Agreements related to the manufacture and release of substances regulated by the FDA.2 A similar template has been developed by the International Pharmaceutical Consortium on Regulation and Science (IPAC-RS) for use by drug manufacturers and suppliers when addressing raw materials, container closure/device components and packaging materials.3 The BPSA, through its Singleuse System Quality Agreement Template Task Force, is adapting the content of these guides to develop a template specific to singleuse manufacturing. This is intended to simplify and standardise the otherwise timeconsuming and sometimes difficult process of negotiating quality agreements between biopharm or vaccine manufacturers and singleuse system or component suppliers.

To further discuss this topic and provide opportunity for users and suppliers to provide input, BPhI and the BPSA are collaborating to produce a web seminar on Quality Agreements for single use manufacturing. The seminar is scheduled for Wednesday 2 March (7 am PST; 10 am EST; 3 pm GMT, 4 pm CET). For more details, see: http://biopharminternational.findpharma.com/webcasts

The BPSA will also be hosting its inaugural International SingleUse Summit (ISUS) in Washington DC (USA; 27–29 July). The meeting will focus on the future of biopharmaceutical manufacturing, with a specific emphasis on regulatory considerations and perspectives on the impact of healthcare reform on drug markets. Innovations and market drivers affecting the singleuse Industry will also be discussed. More information is available at http://www.bpsalliance.org.

In my next column, I'll be reporting on global issues, as well as the implementation of singleuse based on participation as a speaker and panelist at several international meetings including the ISPE Japan Sterile Products Processing Community of Practice Meeting in Japan (17 February), the ISPE Aseptic Processing Seminar in Tampa (Florida, USA; 21–22 February) and the IBC Biomanufacturing and SingleUse Systems Asia Conference in China (7–9 March).

In the interim, feel free to send me suggestions on topics, issues and technology that impact your implementation of single-use. I look forward to hearing from you.

Jerold Martin is Senior VP of Global Scientific Affairs at Pall Life Sciences, Biopharmaceuticals Group, and Chairman of the Board and Technology Committee of the BioProcess Systems Alliance (BPSA). He is also a member of Pharmaceutical Technology Europe's Editorial Advisory Board.

References

1. FDA, Guidance for Industry: Cooperative Manufacturing Arrangements for Licensed Biologics (November 2008). http://www.fda.gov

2. SOCMA BPTF, Manufacturer's Quality Agreement Template (April, 2010). http://www.socma.com

3. IPAC-RS, Quality Agreement Template Toolkit (May, 2009). http://ipacrs.com


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here